ARCHIVES

Long-Term Effect Of One Phase III Trial: Benefit For Thousands Of Patients

This article is from The Cancer Letter archive.

Vol. 32 No. 11 | November 27, 2009

Download PDF Visit The Full Archive

Related Articles

FDA Approves Molecular Test For Breast Cancer Detection

July 27, 2007

Also in this 8-page issue: Amgen names PhRMA executive Rodger Currie vice president for government affairs.

April 30, 2004

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

January 25, 2013

Firm To Study Imaging System As Adjunct To Mammogram.

February 25, 2000

Timeline Pinpoints the Role of Cancer Scandal In a Progression Leading to Perry’s Indictment

September 5, 2014

“Withheld” News Release On QRA Policies Released

November 11, 1983